Pfizer Signs Partnership Deal with ICON and PAREXEL

Pfizer has selected Boston-based Parexel, and Dublin, Ireland-based Icon, as its two preferred CROs for the provision of clinical development and trials services.

Pfizer has selected Boston-based PAREXEL International and Dublin, Ireland-based ICON plc as its two preferred providers for clinical trial services.

Pharmaceutical research contractor PAREXEL will work with Pfizer under a five-year agreement to provide clinical development services and expertise on a global basis combined with its eClinical technology platform.

Under the partnership agreement with ICON, Pfizer will leverage ICON’s expertise in the areas of program initiation and management, site and country feasibility, data management and reporting set-up, program study drug logistics, scientific and medical communications, and quality assurance. Pfizer will retain scientific ownership of the clinical development process, and maintain oversight and quali